MGNX vs SABS
MGNX: A clinical-stage biotechnology company leveraging proprietary bispecific DART technology and antibody-drug conjugates to develop novel cancer immunotherapies. SABS: SAB Biotherapeutics is developing a platform of transchromosomic cattle to produce fully human, high-potency polyclonal antibodies to treat autoimmune diseases like Type 1 Diabetes.
Side-by-side fundamentals
| Metric | MGNX | SABS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $3.55 | $2.89 | |
| Market cap | $226M | $263M | |
| Net margin FY2025, SEC XBRL | -49.9% | n/a | |
| Operating margin FY2025, SEC XBRL | -48.7% | n/a | |
| ROE FY2025, SEC XBRL | -134.2% | +8.8% | SABS higher |
| ROA FY2025, SEC XBRL | -29.1% | +7.7% | SABS higher |
| Debt / equity as of 2026-09-03 | 3.24 | 0.01 | SABS lower |
| Revenue growth (YoY) as of 2026-09-03 | +2.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -0.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.55 | 0.90 | |
| 1-year return as of 2026-10-08 close | +99.4% | +23.5% | MGNX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.